Natural Product (NP) Details
| General Information of the NP (ID: NP8797) | |||||
|---|---|---|---|---|---|
| Name |
Celastrol
|
||||
| Synonyms |
Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid
Click to Show/Hide
|
||||
| Species Origin | Celastrus orbiculatus ... | Click to Show/Hide | |||
| Celastrus orbiculatus | |||||
| Celastrus scandens | |||||
| Tripterygium regelii | |||||
| Celastrus strigillosus | |||||
| Crossopetalum gaumeri | |||||
| Disease | Amyotrophic lateral sclerosis [ICD-11: 8B60] | Preclinical | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C29H38O4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C)O
|
||||
| InChI |
1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1
|
||||
| InChIKey |
KQJSQWZMSAGSHN-JJWQIEBTSA-N
|
||||
| CAS Number |
CAS 34157-83-0
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-MEL-19 | CVCL_6025 | Cutaneous melanoma | Homo sapiens | ||
| SK-MEL-100 | CVCL_6067 | Cutaneous melanoma | Homo sapiens | |||
| SK-MEL-173 | CVCL_6090 | Melanoma | Homo sapiens | |||
| SK-MEL-192 | CVCL_6101 | Melanoma | Homo sapiens | |||
| Experimental
Result(s) |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Celastrol treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus. | |||||
| Apatinib | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax. | |||||
| Lapatinib | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| BT-20 | CVCL_0178 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
| In-vivo Model | Four to six week old female NOD-SCID mice received sub-cutaneous 17Beta-estradiol pellet (0.72 mg/day), 2 weeks prior to injection of 5 * 106 BT-474 cells resuspended in 4% Matrigel. | |||||
| Experimental
Result(s) |
Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol. | |||||
| Trastuzumab | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| BT-20 | CVCL_0178 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
| In-vivo Model | Four to six week old female NOD-SCID mice received sub-cutaneous 17Beta-estradiol pellet (0.72 mg/day), 2 weeks prior to injection of 5 * 106 BT-474 cells resuspended in 4% Matrigel. | |||||
| Experimental
Result(s) |
Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab, producing higher cytotoxicity with substantially lower doses of Celastrol. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| HCC15 | CVCL_2057 | Lung squamous cell carcinoma | Homo sapiens | |||
| Calu-3 | CVCL_0609 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species. | |||||
| TRAIL/Apo2L | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-8 | CVCL_1629 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| PLA-801D | CVCL_7110 | Lung giant cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol. | |||||
| Bortezomib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CXCR4 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | ||
| NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | |||
| KMS-11 | CVCL_2989 | Plasma cell myeloma | Homo sapiens | |||
| In-vivo Model | Male athymic balb/c nude mice were implanted with 2 * 106 cells with Human MM U266 cell lines subcutaneously. | |||||
| Experimental
Result(s) |
Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. | |||||
| Vorinostat | Mycosis fungoides | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PLA-801D | CVCL_7110 | Lung giant cell carcinoma | Homo sapiens | ||
| In-vivo Model | Human lung cancer xenografts were established by subcutaneously inoculating 5*106 95-D cells into nude mice. | |||||
| Experimental
Result(s) |
The synergistic anticancer effects of celastrol and SAHA was demonstrated due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin. | |||||
| ABT-737 | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PMAIP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa. | |||||
| Carboplatin | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Induction | Degradation | FANCD2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HSJD-DIPG-07 | CVCL_VU70 | Diffuse intrinsic pontine glioma | Homo sapiens | ||
| JHH-DIPG-1 | CVCL_IT47 | Diffuse intrinsic pontine glioma | Homo sapiens | |||
| SU-DIPG-IV | CVCL_IT39 | Diffuse intrinsic pontine glioma | Homo sapiens | |||
| SU-pcGBM-2 | CVCL_IT42 | Glioblastoma | Homo sapiens | |||
| VUMC-DIPG-10 | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-DIPG-F | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-DIPG-G | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-HGG-09 | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-HGG-14 | Pediatric high-grade gliomas | Homo sapiens | ||||
| VUMC-HGG-11 | Pediatric high-grade gliomas | Homo sapiens | ||||
| In-vivo Model | VUMC-HGG-14 cells (50*104 cells in 5 uL) were stereotactically injected into the striatum (4-week old female athymic nude mice). | |||||
| Experimental
Result(s) |
Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [11] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CERS1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CERS4 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CERS6 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | CT26 | CVCL_7254 | Mouse colon adenocarcinoma | Mus musculus | ||
| HCT 8 | CVCL_2478 | Colon adenocarcinoma | Homo sapiens | |||
| DLD-1 | CVCL_0248 | Colon adenocarcinoma | Homo sapiens | |||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| In-vivo Model | BALB/c mice were removed hair and injected CT26 cells (1.5*106) suspended in FBS: Matrigel (1:1, 200 uL/mouse) subcutaneously in the flank region of mice. | |||||
| Experimental
Result(s) |
Hydrogel-mediated delivery of celastrol and doxorubicin induces a synergistic effect on tumor regression via upregulation of ceramides. | |||||
| PHA665752 | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [12] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Male nude mice (4-6 weeks) were inoculated subcutaneously with human liver cancer cell lines Huh7. | |||||
| Experimental
Result(s) |
Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. | |||||
| Tanespimycin | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [13] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Proteotoxic stress | ||||
| In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
| U-343MG | CVCL_S471 | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
celastrol targets proteostasis by disrupting sulfyhydryl homeostasis, independently of ROS, in human glioblastoma cells. Targeting proteotoxic stress responses by inhibiting HSP90 with 17-N-Allylamino-17-demethoxygeldanamycin sensitizes human glioblastoma to celastrol treatment, thereby serving as a novel synergism to overcome drug resistance. | |||||
| Afatinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [14] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Mitochondrial Ca2+ overload | ||||
| Induction | ROS accumulation | |||||
| In-vitro Model | NCI-H23 | CVCL_1547 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H292 | CVCL_0455 | Lung mucoepidermoid carcinoma | Homo sapiens | |||
| In-vivo Model | A volume of 100 ul H23 cell suspension (1 * 108 cells/ml in normal saline) was subcutaneously injected into the right flanks of mouse (male BALB/c nude mice of 4-5 weeks old). | |||||
| Experimental
Result(s) |
Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [15] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SPC25 | Molecule Info | ||
| In-vitro Model | SAS | CVCL_1675 | Tongue squamous cell carcinoma | Homo sapiens | ||
| CGHNC8 | Oral squamous cell carcinoma cells | Homo sapiens | ||||
| Experimental
Result(s) |
Celastrol effectively inhibit SPC25 expression and reverse CR phenotype. | |||||
| Erlotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [16] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Each mouse (five-week-old BALB/c nude mice) was subcutaneously injected with 2 * 106 H1975 lung carcinoma cells in logarithmic growth phase. | |||||
| Experimental
Result(s) |
Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. | |||||
| Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [16] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Each mouse (five-week-old BALB/c nude mice) was subcutaneously injected with 2 * 106 H1975 lung carcinoma cells in logarithmic growth phase. | |||||
| Experimental
Result(s) |
Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Interleukin-1 beta (IL1B) | Molecule Info | [1] | |
| Tumor necrosis factor (TNF) | Molecule Info | [1] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Cytokine-cytokine receptor interaction | |||
| 3 | NF-kappa B signaling pathway | |||
| 4 | Sphingolipid signaling pathway | |||
| 5 | mTOR signaling pathway | |||
| 6 | Apoptosis | |||
| 7 | TGF-beta signaling pathway | |||
| 8 | Osteoclast differentiation | |||
| 9 | Antigen processing and presentation | |||
| 10 | Toll-like receptor signaling pathway | |||
| 11 | NOD-like receptor signaling pathway | |||
| 12 | RIG-I-like receptor signaling pathway | |||
| 13 | Hematopoietic cell lineage | |||
| 14 | Natural killer cell mediated cytotoxicity | |||
| 15 | T cell receptor signaling pathway | |||
| 16 | Fc epsilon RI signaling pathway | |||
| 17 | TNF signaling pathway | |||
| 18 | Adipocytokine signaling pathway | |||
| 19 | Type II diabetes mellitus | |||
| 20 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 21 | Type I diabetes mellitus | |||
| 22 | Alzheimer's disease | |||
| 23 | Amyotrophic lateral sclerosis (ALS) | |||
| 24 | Pertussis | |||
| 25 | Legionellosis | |||
| 26 | Leishmaniasis | |||
| 27 | Chagas disease (American trypanosomiasis) | |||
| 28 | African trypanosomiasis | |||
| 29 | Malaria | |||
| 30 | Toxoplasmosis | |||
| 31 | Amoebiasis | |||
| 32 | Tuberculosis | |||
| 33 | Hepatitis C | |||
| 34 | Hepatitis B | |||
| 35 | Influenza A | |||
| 36 | HTLV-I infection | |||
| 37 | Herpes simplex infection | |||
| 38 | Proteoglycans in cancer | |||
| 39 | Asthma | |||
| 40 | Inflammatory bowel disease (IBD) | |||
| 41 | Systemic lupus erythematosus | |||
| 42 | Rheumatoid arthritis | |||
| 43 | Allograft rejection | |||
| 44 | Graft-versus-host disease | |||
| 45 | Hypertrophic cardiomyopathy (HCM) | |||
| 46 | Dilated cardiomyopathy | |||
| 47 | Cytosolic DNA-sensing pathway | |||
| 48 | Inflammatory mediator regulation of TRP channels | |||
| 49 | Prion diseases | |||
| 50 | Salmonella infection | |||
| 51 | Measles | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | IL3 Signaling Pathway | |||
| 4 | IL4 Signaling Pathway | |||
| 5 | Leptin Signaling Pathway | |||
| 6 | RANKL Signaling Pathway | |||
| 7 | IL1 Signaling Pathway | |||
| 8 | IL5 Signaling Pathway | |||
| 9 | TGF_beta_Receptor Signaling Pathway | |||
| 10 | Wnt Signaling Pathway | |||
| 11 | TNFalpha Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | Wnt signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
| Pathway Interaction Database | IL27-mediated signaling events | Click to Show/Hide | ||
| 2 | Canonical NF-kappaB pathway | |||
| 3 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 4 | Angiopoietin receptor Tie2-mediated signaling | |||
| 5 | Signaling events mediated by HDAC Class I | |||
| 6 | TNF receptor signaling pathway | |||
| 7 | Ceramide signaling pathway | |||
| 8 | amb2 Integrin signaling | |||
| 9 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 10 | IL23-mediated signaling events | |||
| 11 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 12 | Caspase Cascade in Apoptosis | |||
| 13 | Cellular roles of Anthrax toxin | |||
| 14 | Downstream signaling in naï | |||
| 15 | ||||
| 16 | IL12-mediated signaling events | |||
| 17 | IL1-mediated signaling events | |||
| 18 | IFN-gamma pathway | |||
| Reactome | Transcriptional regulation of white adipocyte differentiation | Click to Show/Hide | ||
| 2 | TNFR1-induced proapoptotic signaling | |||
| 3 | Regulation of TNFR1 signaling | |||
| 4 | TNFR1-induced NFkappaB signaling pathway | |||
| 5 | TNFR1-mediated ceramide production | |||
| 6 | TNFR2 non-canonical NF-kB pathway | |||
| 7 | TNF signaling | |||
| 8 | Interleukin-1 signaling | |||
| 9 | Interleukin-1 processing | |||
| 10 | CLEC7A/inflammasome pathway | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Monoamine Transport | |||
| 3 | SIDS Susceptibility Pathways | |||
| 4 | TGF Beta Signaling Pathway | |||
| 5 | Cytokines and Inflammatory Response | |||
| 6 | MAPK Signaling Pathway | |||
| 7 | EV release from cardiac cells and their functional effects | |||
| 8 | FAS pathway and Stress induction of HSP regulation | |||
| 9 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 10 | Cardiac Hypertrophic Response | |||
| 11 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 12 | Aryl Hydrocarbon Receptor | |||
| 13 | Apoptosis | |||
| 14 | Nanoparticle triggered regulated necrosis | |||
| 15 | Amyotrophic lateral sclerosis (ALS) | |||
| 16 | Adipogenesis | |||
| 17 | Allograft Rejection | |||
| 18 | TNF alpha Signaling Pathway | |||
| 19 | TWEAK Signaling Pathway | |||
| 20 | Extrinsic Pathway for Apoptosis | |||
| 21 | Folate Metabolism | |||
| 22 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 23 | Vitamin B12 Metabolism | |||
| 24 | Selenium Micronutrient Network | |||
| 25 | Regulation of toll-like receptor signaling pathway | |||
| 26 | Matrix Metalloproteinases | |||
| 27 | TCR Signaling Pathway | |||
| 28 | Type II interferon signaling (IFNG) | |||
| 29 | Senescence and Autophagy in Cancer | |||
| 30 | Myometrial Relaxation and Contraction Pathways | |||
| 31 | Aryl Hydrocarbon Receptor Pathway | |||
| 32 | IL1 and megakaryotyces in obesity | |||
| 33 | Hematopoietic Stem Cell Differentiation | |||
| 34 | Spinal Cord Injury | |||
| 35 | Alzheimers Disease | |||
| 36 | Leptin signaling pathway | |||
| 37 | IL-1 signaling pathway | |||
| 38 | Interleukin-1 signaling | |||
| 39 | Serotonin Transporter Activity | |||
| 40 | NOD pathway | |||
